XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Clinical Trials Channel
subscribe to Clinical Trials newsletter

Latest Research : Clinical Trials

   DISCUSS   |   EMAIL   |   PRINT
EU clinical trials directive is threatening future of cancer research
Mar 4, 2006 - 3:14:00 PM, Reviewed by: Dr. Priya Saxena

These numbers seem to confirm the initial worries about the future of investigator initiated clinical cancer research, say the authors. Current and future patients with metastatic cancer should be worried. If research is thwarted the newest or most effective therapies may not become available rapidly.

 
A new European directive is threatening the future of cancer research in Europe, warn experts in this week�s BMJ.

The EU clinical trials directive, implemented in 2004, was intended to protect patients and improve research standards. But many investigators were worried that the labour intensive, bureaucratic, and expensive endeavour of running a clinical trial would become worse under the new rules.

In particular, academic researchers funded by grants, who have so far performed most cancer trials, were worried that their resources might no longer suffice to meet the requirements of the new directive.

An analysis of research since the directive suggests that many of those fears have been realised. For example, the number of new trials fell from 19 in 2004 to 7 in 2005 (63% decrease), and a third fewer patients were enrolled.

Simultaneously, trial costs increased by 85% and insurance costs from 70 to 140 million euros. Trial initiation was about five months slower than in 2004, while paperwork and documentation increased.

Instead of benefiting patients, the analysis suggests that the directive had hindered their access to new treatments.

�Our own experiences are in accordance with these findings,� say the authors. The number of approved applications for both academic and company sponsored cancer trials in Helsinki has steadily decreased from 120 in 2002 to 70 in 2005 (42% decrease), but the workload of the ethics committee has increased.

These numbers seem to confirm the initial worries about the future of investigator initiated clinical cancer research, say the authors. Current and future patients with metastatic cancer should be worried. If research is thwarted the newest or most effective therapies may not become available rapidly, they warn.

New directives on clinical research are in preparation. Therefore, now is the time for action by physicians, patients, universities, and politicians to ensure that academic research can continue in Europe. It is in no one�s interest if only commercial corporations have the resources to plan and carry out clinical trials, they conclude.
 

- British Medical Journal
 

http://bmj.com/cgi/content/full/332/7540/501

 
Subscribe to Clinical Trials Newsletter
E-mail Address:

 



Related Clinical Trials News
Probiotics unsafe for severe acute pancreatitis patient's due to its increased mortality.
Start of Second Phase III Trial in MS Neuropathic Pain
RISUG (Reversible Inhibition of Sperm Under Guidance) Trial to recruit more volunteers
EU clinical trials directive is threatening future of cancer research
Lessons from natalizumab fast tracking in multiple sclerosis
First human trial of recombinant ricin vaccine completed
New stem cell study seeks to prevent heart failure
Electronic health record-based clinical trial alert system increased recruitment rates
Study of New, Non-Growth Hormone Treatment for Short Stature


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us